Abstract
Illicit opiate use in Canada causes considerable harm and social cost. Methadone substitution treatment, which has been proven effective in reducing the negative effects associated with opiate use, has been used in Canada, but so far only on a small scale. Recent research suggests that, while expanding the availability of methadone substitution is certainly in the public health interest, it would not be sufficient in itself to reduce to a minimum the harms from illicit opiate use. On the basis of the epidemiology of opiate use and of related harms, and building on the experience of intervention efforts currently underway elsewhere, this paper argues for the establishment of a heroin substitution trial in Canada. Such a trial should have the goal of investigating the potential of heroin substitution to significantly reduce the health and social costs to Canadians from illicit opiate use.
Résumé
La consommation illégale d’opiacés au Canada est responsable de méfaits considérables et d’un lourd fardeau social. Le traitement de substitution à la méthadone a fait ses preuves quant à son efficacité à réduire les effets néfastes associés à l’usage d’opiacés. On y a recours au Canada, mais à petite échelle seulement. Des recherches menées récemment laissent supposer que bien qu’il serait dans l’intérêt de la santé publique de multiplier le nombre de programmes de traitement à la méthadone, cette mesure serait insuffisante en soi pour réduire au minimum les méfaits causés par l’usage illégal d’opiacés. Le présent article plaide pour qu’un essai de traitement de substitution de l’héroïne soit tenu au Canada. Il est fondé sur l’étude de l’épidémiologie de l’usage d’opiacés et de ses méfaits, et des interventions mises de l’avant à l’étranger. Un essai semblable aurait pour objectif d’investiguer le potentiel de la substitution de l’héroïne à réduire considérablement les fardeaux sociaux et de santé liés à l’usage illégal d’opiacés au Canada.
Footnotes
The views expressed in this paper are those of the authors and do not necessarily reflect the views of the Addiction Research Foundation or the University of Toronto.
References
- 1.Information Canada. Commission of Inquiry into the Non-Medical Use of Drugs. Final Report. 1973. [Google Scholar]
- 2.Information Canada. Commission of Inquiry into the Non-Medical Use of Drugs. 1972. [Google Scholar]
- 3.Hser YI. Prevalence estimation: Summary of common problems and practical solutions. J Drug Issues. 1993;23:335–43. doi: 10.1177/002204269302300211. [DOI] [Google Scholar]
- 4.Hser YI. Prevalence estimation techniques for drug-using populations. Data sources: Problems and issues. J Drug Issues. 1993;23:217–28. doi: 10.1177/002204269302300205. [DOI] [Google Scholar]
- 5.Simeone RS, Nottingham WT, Holland L. Estimating the size of heroin-using population: An examination of the use of treatment admissions data. Int J Addictions. 1993;28:107–28. doi: 10.3109/10826089309039618. [DOI] [PubMed] [Google Scholar]
- 6.Statistics Canada. Canada’s Alcohol and Other Drugs Survey. Ottawa: Health Canada; 1994. [Google Scholar]
- 7.Turner CF, Lessler JT, Gfroerer JC. Survey Measurement of Drug Use: Methodological Studies. National Institute on Drug Abuse, U.S. Department of Health and Human Services. 1992. [Google Scholar]
- 8.Rehm J, et al. Modes de consommation et répartition des drogues en Suisse. In: Fahrenkrug H, Rehm J, Müller R, et al., editors. Drogues illégales en Suisse 1990–1993. La situation dans les cantons et en Suisse. Zürich: Seismo; 1995. pp. 13–34. [Google Scholar]
- 9.Baden M. Narcotic abuse: A medical examiner’s view. In: Wecht CH, editor. Legal Medicine Annual. New York: Appleton Century-Crofts; 1971. [PubMed] [Google Scholar]
- 10.Single E, Robson L, Xie X, Rehm J i c w, Moore R, Choi B, Desjardins S, Anderson J. The Costs of Substance Abuse in Canada. Ottawa: Canadian Centre on Substance Abuse; 1996. [Google Scholar]
- 11.Rehm J, Ialomiteanu A, Walsh G, et al. The Quantification of Mortality Caused by Illicit Drugs in Canada, 1992. Toronto: Addiction Research Foundation; 1996. [Google Scholar]
- 12.Remis RS, Leclerc P, Routledge R, et al. Consortium to characterize injection drug users in Canada. Proposal to NHRDP. 1996. [Google Scholar]
- 13.Southtown Consulting. Heroin activity in metropolitan Toronto (study conducted for MTATSC) 1995. [Google Scholar]
- 14.Nadelmann E, McNeely J, Drucker E. Harm reduction drug control strategies: A global perspective. In: Lowinson J, Ruiz P, Millman R, editors. Substance Abuse: A Comprehensive Textbook. Baltimore: Williams and Wilkins; 1997. [Google Scholar]
- 15.Hankins C, Barlow K, Black S, et al. HIV, AIDS and Injection Drug Use. Ottawa: Health Canada; 1997. [Google Scholar]
- 16.Strathdee S, Patrick D, Currie S, et al. Needle exchange is not enough: Lessons from the Vancouver injecting drug use study. AIDS 1997;11:F59-F65. [DOI] [PubMed]
- 17.Department of HealthHuman Services. Methadone maintenance treatment Translating research into policy; 1995. [Google Scholar]
- 18.Xie X, Rehm J, Single E, Robson L. The Economic Costs of Alcohol, Tobacco and Illicit Drug Abuse in Ontario: 1992. Toronto: Addiction Research Foundation; 1996. [Google Scholar]
- 19.Bureau of Drug Surveillance. Data on methadone maintenance programs in Canada, unpublished. Ottawa: Health Canada; 1997. [Google Scholar]
- 20.Dole V, Nyswander M. The use of methadone for narcotic blockade. Br J Addiction. 1968;63:55–57. doi: 10.1111/j.1360-0443.1968.tb05251.x. [DOI] [PubMed] [Google Scholar]
- 21.Hubbard RI, Marsden, ME. Relapse to use of heroin, cocaine and other drugs in the first year after treatment. In: NIDA Research Monograph 72, U, Ed. Relapse and Recovery in Drug Abuse. Rockville, MD, 1986. [PubMed]
- 22.Senay E, Uchtenhagen A. Methadone in the treatment of opioid dependence: A review of the world literature. In: Arif A, Westermeyer J, editors. Methadone Maintenance in the Management of Opioid Dependence. New York: Praeger; 1990. [Google Scholar]
- 23.Ball J, Ross A. The Effectiveness of Methadone Maintenance Treatment: Patients, Programs, Services and Outcomes. New York: Springer- Verlag; 1991. [Google Scholar]
- 24.Institute of Medicine. Federal Regulation of Methadone Treatment. Washington, DC: National Academy Press; 1995. [Google Scholar]
- 25.Nadelmann E, McNeely J. Doing methadone right. The Public Interest 1996;123, Spring.
- 26.Giffen JP, Endicott S, Lambert S. Panic and indifference — The politics of Canada’s drug laws. Ottawa: Canadian Centre on Substance Abuse; 1991. [Google Scholar]
- 27.Halliday R. Management of the narcotic addict. BC Medical Journal. 1963;5:412–14. [Google Scholar]
- 28.Non-Medical Use of Drugs Directorate. Trends in methadone use in the treatment of opiate dependence in Canada. Ottawa: Health and Welfare Canada; 1976. [Google Scholar]
- 29.Peachey JE, Franklin T. Methadone treatment of opiate dependence in Canada. Br J Addiction. 1985;80:291–99. doi: 10.1111/j.1360-0443.1985.tb02542.x. [DOI] [PubMed] [Google Scholar]
- 30.The College of PhysiciansSurgeons in Ontario. Methadone maintenance guidelines. 1996. [Google Scholar]
- 31.International survey on the use of methadone in the treatment of narcotic addiction . Summary of results. Ottawa: Health Canada; 1996. [Google Scholar]
- 32.Swiss methadone report. Berne/Toronto: Swiss Federal Office of Public Health/Addiction Research Foundation. 1996. [Google Scholar]
- 33.Fischer B. Drug, communities and ‘harm reduction’ in Germany: The new relevance of ‘public health’ principles in local responses. J Public Health Pol. 1995;16:389–411. doi: 10.2307/3342618. [DOI] [PubMed] [Google Scholar]
- 34.Bossong H. Methadon-Substitutionsbehandlung. Das Grüene Gehirn-Der Arzt im Öffentlichen Gesundheitswesen. 36: Erg, 1995.
- 35.Bossong H, Stöver H. Methadonbehandlung. Campus: Frankfurt; 1992. [Google Scholar]
- 36.Sells SB, Demaree RG, Hornick CW. Comparative effectiveness of drug abuse treatment modalities. NIDA Services Research Administrative Report. 1979. [Google Scholar]
- 37.Fischer B, Medved W, Rehm J, Gliksman L. Profile of illicit and un-treated opiate users in Toronto, Canada. Addiction Research under review.
- 38.Hubbard RL, Marsden ME, Rachal JV, et al. Drug Abuse Treatment: A National Study of Effectiveness. Chapel Hill: University of North Carolina Press; 1989. [Google Scholar]
- 39.Simpson DD, Sells SB. Effectiveness of treatment for drug abuse: An overview of the DARP research program. Advances in Alcohol and Substance Abuse. 1982;2:7–29. doi: 10.1300/J251v02n01_02. [DOI] [Google Scholar]
- 40.Maddux JF, Vogtsberger KN, Desmond DP, Esquivel M. Program changes and retention on methadone. J Substance Abuse Treatment. 1993;10:585–88. doi: 10.1016/0740-5472(93)90063-8. [DOI] [PubMed] [Google Scholar]
- 41.Kreek MJ. Methadone in treatment: Physiological and pharmacological issues. In: DuPont RL, Goldstein A, O’Donnell J, Brown B, editors. Handbook on Drug Abuse. Rockville, MD: National Institute on Drug Abuse; 1979. [Google Scholar]
- 42.Kreek MJ. Medical safety and side effects of methadone in tolerant individuals. J Psychoactive Drugs. 1991;23:6. [PubMed] [Google Scholar]
- 43.Jaffe JH, Martin WR, et al. Opioid analgesics and antagonists. In: Goodman Gilman A, Goodman L, Rall T, et al., editors. Goodman and Gilman’s The Pharmacological Basis of Therapeutics. New York: Pergamon Press; 1985. pp. 491–532. [Google Scholar]
- 44.Grund J-PC. Drug use as a social ritual: Functionality, symbolism and determinants of self-regulation. Rotterdam: IVO (Addiction Research Institute); 1993. [Google Scholar]
- 45.Uchtenhagen A, Gutzwiller F, Dobler-Mikola A. Versuche für eine ärztliche Verschreibung von Betäubungsmitteln. Institut für Suchtforschung in Verbindung mit der Universität Zürich. 1996. [Google Scholar]
- 46.Bammer G, Dance P, Stevens A, et al. Attitudes to a proposal for controlled availability of heroin in Australia: Is it time for a trial? Addiction Research. 1996;4:45–55. doi: 10.3109/16066359609005562. [DOI] [Google Scholar]
- 47.Böllinger L. German drug laws in the context of international pressure and internal conflicts — A theoretical approach to the evolution of drug policy. 1996. [Google Scholar]